Cancer and clinical oncology最新文献_第7页

Cell Growth Regulated by Syndecan-1 in Human Liposarcoma Syndecan-1调控人脂肪肉瘤细胞生长

Cancer and clinical oncology Pub Date : 2015-04-23 DOI: 10.5539/CCO.V4N1P58

S. Tsukamoto, K. Shimada, K. Honoki, A. Kido, M. Akahane, Yasuhito Tanaka, N. Konishi

{"title":"Cell Growth Regulated by Syndecan-1 in Human Liposarcoma","authors":"S. Tsukamoto, K. Shimada, K. Honoki, A. Kido, M. Akahane, Yasuhito Tanaka, N. Konishi","doi":"10.5539/CCO.V4N1P58","DOIUrl":"https://doi.org/10.5539/CCO.V4N1P58","url":null,"abstract":"Background: The heparan sulfate proteoglycan, syndecan-1 (also known as CD138), is associated with cell proliferation, adhesion, and migration in various types of human malignancies. The role of syndecan-1 in soft tissue tumors is unknown; therefore we examined whether syndecan-1 plays a role in human liposarcoma. Materials and Methods: We performed immunohistochemical analyses of syndecan-1 in 42 liposarcoma cases, including 21 myxoid liposarcoma cases. Recurrence-free survival was estimated by the Kaplan–Meire method. We examined the association between apoptosis and syndecan-1 gene silencing in a human liposarcoma cell line. Results: The proportion of syndecan-1 positive cells (?10%) was significantly associated with unfavorable recurrence-free survival in myxoid liposarcoma patients. There were no significant associations between syndecan-1 expression and prognosis in the other subtypes of liposarcoma. Knockdown of syndecan-1 induced apoptosis and suppression of cell growth in vitro . Conclusion: Syndecan-1 could be a novel prognostic factor for myxoid liposarcoma recurrence and a new therapeutic target for human myxoid liposarcoma.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"4 1","pages":"58"},"PeriodicalIF":0.0,"publicationDate":"2015-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V4N1P58","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70722508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sacral Nerve Hemangiopericytoma: A Rare Case and Review of the Literature 骶神经血管外皮细胞瘤一例及文献复习

Cancer and clinical oncology Pub Date : 2015-03-30 DOI: 10.5539/CCO.V4N1P47

Osama Ahmed, R. Menger, Sunil Kukreja, Shihao Zhang, Christopher Storey, A. Nanda, Bharat Guthikonda

{"title":"Sacral Nerve Hemangiopericytoma: A Rare Case and Review of the Literature","authors":"Osama Ahmed, R. Menger, Sunil Kukreja, Shihao Zhang, Christopher Storey, A. Nanda, Bharat Guthikonda","doi":"10.5539/CCO.V4N1P47","DOIUrl":"https://doi.org/10.5539/CCO.V4N1P47","url":null,"abstract":"Introduction: Hemangiopericytomas usually occur in the soft tissue and skeletal system. They rarely present in the spinal canal as a primary tumor. There are several case reports describing primary spinal hemangiopericytomas of the cervical and thoracic spine; however, there are only 3 reports of sacral hemangioperictyomas (Liu, 2013; McMaster, 1975; Zhao, 2007). We report an extremely rare presentation of a primary spinal hemangiopericytoma arising from the S2 nerve root with local bony destruction of the sacrum. Case Report: A 52 year-old male presented with low back pain and left lower extremity numbness and tingling. MRI showed a 5.2 cm x 5.7 cm sacral mass, and CT showed local bony destruction of the sacrum. He complained of left S2 pain. The patient was taken for resection of the tumor. A gross total resection was achieved from a posterior midline approach. A corridor lateral to the sacral nerves allows resection of the ventral portion of the tumor. A gross total resection was achieved with a small residual adherent to the left S2 nerve root. Pathology confirmed the tumor to be a grade II hemangiopericytoma. Adjuvant radiotherapy was recommended due to the residual.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"4 1","pages":"47"},"PeriodicalIF":0.0,"publicationDate":"2015-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V4N1P47","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70722496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary CNS Malignant Melanoma Associated With a Contralateral Nevus of Ota in an African-American Female: Unique Case Report 非裔美国女性原发性中枢神经系统恶性黑色素瘤伴对侧太田痣:独特病例报告

Cancer and clinical oncology Pub Date : 2015-03-23 DOI: 10.5539/CCO.V4N1P39

Bharat Guthikonda, Osama Ahmed, Linda J Buckleair, J. Goodman, S. Powell, D. Yoshor

{"title":"Primary CNS Malignant Melanoma Associated With a Contralateral Nevus of Ota in an African-American Female: Unique Case Report","authors":"Bharat Guthikonda, Osama Ahmed, Linda J Buckleair, J. Goodman, S. Powell, D. Yoshor","doi":"10.5539/CCO.V4N1P39","DOIUrl":"https://doi.org/10.5539/CCO.V4N1P39","url":null,"abstract":"Background: Primary CNS melanoma is a rare neoplasm of the brain. Nevus of Ota is an area of macular, melanocytic pigmentation of the sclera and skin around the eye. Association between intracranial melanocytic neoplasms and Nevus of Ota has previously been described in case reports. The two lesions tend to occur ipsilaterally and in Caucasian patients. We present the first documented case of a primary malignant CNS melanoma contralateral to a Nevus of Ota in an African-American patient. Case Discussion: A 32-year-old female presented with intermittent numbness involving the left side of her face, arm, and leg. General physical exam revealed a large area of hyperpigmentation involving the left side of her face, especially around the eye and upper cheek, consistent with Nevus of Ota. Neuroimaging revealed a hemorrhagic intraparenchymal mass in the right frontotemporal region. Surgical resection of the lesion was performed, and pathology was consistent with primary CNS malignant melanoma. Conclusion: Primary CNS melanocytic neoplasms and Nevus of Ota share a similar embryological origin. Thus, the associated occurrence of the two is not surprising. We present a unique case of primary CNS malignant melanoma associated with a contralateral Nevus of Ota in an African-American patient. Primary CNS melanoma should be considered in the differential diagnosis of any patient with a Nevus of Ota who is found to have an intracranial mass.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"4 1","pages":"39"},"PeriodicalIF":0.0,"publicationDate":"2015-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V4N1P39","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70722451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Quality of Life Among Cancer Patients Treated With Chemotherapy or Radiotherapy in Erbil City An Evaluation Study 埃尔比勒市接受化疗或放疗的癌症患者生活质量评价研究

Cancer and clinical oncology Pub Date : 2015-03-15 DOI: 10.5539/CCO.V4N1P19

A. Raoof, S. Yacoub, Y. Asaad, T. S. Hadithi

{"title":"Quality of Life Among Cancer Patients Treated With Chemotherapy or Radiotherapy in Erbil City An Evaluation Study","authors":"A. Raoof, S. Yacoub, Y. Asaad, T. S. Hadithi","doi":"10.5539/CCO.V4N1P19","DOIUrl":"https://doi.org/10.5539/CCO.V4N1P19","url":null,"abstract":"Objectives: This study was conducted to assess the quality of life in its different domains among cancer patients in relation to their treatment modality. Methods: A convenience sample of 200 patients with cancer was selected, 100 patients were on chemotherapy and the other 100 were on radiotherapy. Data was obtained through direct interview, using FACT-G questionnaire, version 4, and was managed through a statistical program, using appropriate statistical tests. Results: The emotional domain was the least affected one in both study groups (P = 0.800), while the physical domain reflected a significant statistical differences (P < 0.001); it was mildly affected in 92% of those with radiotherapy and moderately affected in 47% of those on chemotherapy. The social and functional domains were the most badly affected with a significant difference in the functional domain only (P <0.001) where 93% of those on radiotherapy being badly affected. The functional well-being of breast cancer was more affected among those with radiotherapy (P = 0.039), while the physical domains of quality of life of patients with gastrointestinal tract cancer was more badly affected by chemotherapy (P = 0.001). Conclusion: Patients on chemotherapy are more badly affected in some domains of quality of life, compared to those on radiotherapy. The emotional domain of QoL was the least affected, while the social and functional domains were the most badly affected ones among cancer patients, whether they were treated with radiotherapy or chemotherapy.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"4 1","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2015-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V4N1P19","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70722592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Newly-Diagnosed Anaplastic Astrocytoma-Final Report (Protocol BT-08) 抗瘤质体A10和AS2-1在成人新诊断间变性星形细胞瘤患者中的II期研究——最终报告(方案BT-08)

Cancer and clinical oncology Pub Date : 2015-03-15 DOI: 10.5539/CCO.V4N1P28

S. Burzynski, T. Janicki, Gregory S. Burzynski, A. Marszalek

{"title":"A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Newly-Diagnosed Anaplastic Astrocytoma-Final Report (Protocol BT-08)","authors":"S. Burzynski, T. Janicki, Gregory S. Burzynski, A. Marszalek","doi":"10.5539/CCO.V4N1P28","DOIUrl":"https://doi.org/10.5539/CCO.V4N1P28","url":null,"abstract":"The paper reports the evaluation of efficacy and safety of Antineoplastons A10 and AS2-1 (ANP) in a phase II study of newly diagnosed patients with anaplastic astrocytoma (AA). The study was designed as a single-arm, two-stage, phase II trial of ANP as monotherapy. The primary endpoint, was to determine the overall response rate (confirmed complete response (CR) or partial response (PR)) to ANP, based on disappearance or more than 50% reduction of tumor size by contrast-enhanced magnetic resonance imaging (MRI). The goal of the study was a response rate to ANP of not less than 10% or 4 patients. 19 patients (12 men, 7 women) ages 22-60 years (median age, 44) were treated. The patients received ANP daily every four hours (median dose of A10 5.3 g/kg/d and AS2-1 0.3 g/kg/d). The duration of ANP ranged from 3 to 175 weeks. A complete response was documented in 21%, and stable disease in 26% of patients. The study was closed for enrollment after 19 of its subjects had been admitted, because the goal of trial had been accomplished. Progression-free survival and overall survival at 2 years was 16% and 37% and at 10 years was 5% and 14% respectively. Only 11% of patients reported grade 3 toxicities consisting of hypokalemia and fatigue, and 11% reported grade 4 toxicities consisting of hypernatremia and hypokalemia. There was no chronic toxicity and there was a high quality of life. ANP shows efficacy with very good toxicity profile in patients with newly diagnosed AA.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"4 1","pages":"28"},"PeriodicalIF":0.0,"publicationDate":"2015-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V4N1P28","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70722314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

The Insulin-like Growth Factor Axis, Adipokines, Physical Activity, and Obesity in Relation to Breast Cancer Incidence and Recurrence. 胰岛素样生长因子轴、脂肪因子、体力活动和肥胖与乳腺癌发病率和复发的关系

Cancer and clinical oncology Pub Date : 2015-01-01 DOI: 10.5539/cco.v4n2p24

Steven S Coughlin, Selina A Smith

{"title":"The Insulin-like Growth Factor Axis, Adipokines, Physical Activity, and Obesity in Relation to Breast Cancer Incidence and Recurrence.","authors":"Steven S Coughlin, Selina A Smith","doi":"10.5539/cco.v4n2p24","DOIUrl":"https://doi.org/10.5539/cco.v4n2p24","url":null,"abstract":"Background: Obesity, a risk factor for the development of postmenopausal breast cancer and certain other cancer types, has also been associated with poorer response to cancer therapy and cancer recurrence. The insulin-like growth factor (IGF) axis also influences cancer risk.Methods: In this commentary, we consider the literature on IGF and its binding proteins and the risk of breast cancer, along with effects of obesity, adipokines, and insulin resistance on breast cancer, and the potential for lifestyle interventions to address weight gain and physical inactivity among at-risk women.Results: Greater body fatness is associated with a higher risk of postmenopausal breast cancer. The association may be explained, in part, by hyperinsulinemia and alterations in adipokines and estrogens. Nutrition, energy balance, and levels of physical activity are determinants of IGF bioactivity. Alterations in the IGF axis can increase cancer risk and progression. Results from epidemiologic studies indicate that higher circulating levels of IGF-I are associated with an increased risk of breast cancer.Conclusions: Intervention studies are needed to determine how to sustain the positive effects of exercise over time and to identify the optimal mode, intensity, frequency, duration, and timing of exercise for breast cancer survivors, including important subgroups of survivors such as African American and Hispanic women. Future epidemiologic studies of the relationships between the IGF axis and breast cancer should include adequate numbers of African American women, Hispanic women, and other minority women who have been underrepresented in studies completed to date.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"4 2","pages":"24-31"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/cco.v4n2p24","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33903497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 36

Chemoradiation Compared to Surgery Alone in Patients With Non- Metastatic Esophageal Carcinoma 非转移性食管癌患者放化疗与单纯手术的比较

Cancer and clinical oncology Pub Date : 2014-11-26 DOI: 10.5539/CCO.V4N1P1

Mohamed I. El-sayed, D. W. Maximos

{"title":"Chemoradiation Compared to Surgery Alone in Patients With Non- Metastatic Esophageal Carcinoma","authors":"Mohamed I. El-sayed, D. W. Maximos","doi":"10.5539/CCO.V4N1P1","DOIUrl":"https://doi.org/10.5539/CCO.V4N1P1","url":null,"abstract":"Purpose : To assess overall survival (OS) of esophageal cancer patients treated either by esophagectomy or chemoradiation (CRT). Methods: The medical records of patients with non metastatic esophageal cancer, treated with esophagectomy and those treated with concurrent CRT were analyzed. For all patients, files were reviewed for age, sex, tumor site and type, grade, disease stage and survival. The Log- rank test was used to examine differences in OS rates. Results: The medical records of 90 patients were analyzed. After a median follow up of 20 months, 2-year OS rate for the whole group was 46%. There was significant differences in 2-year OS in favor of patients treated by concurrent CRT (55.4%) compared to those treated by surgery (31%) (p=0.016, HR:1.96, 95% CI: 1.13–3.38). Univariate analysis showed that patients in each treatment group, had comparable 2-year OS rates regarding patient’s age, gender, pathologic subtype, and histologic grade (p>0.05). Disease stage in each group and tumor site in CRT group significantly affected OS rates (p<0.05). Conclusions: Survival rates were statistically significant higher in patients treated with CRT than in those underwent esophagectomy. Prognostic factors that affected survival were disease stage in each treatment group and tumor site in CRT group.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"4 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2014-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V4N1P1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70722366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Adjuvant Chemotherapy for Bladder Cancer: One Step Forward, two Steps Back 膀胱癌的辅助化疗:前进一步，后退两步

Cancer and clinical oncology Pub Date : 2014-11-26 DOI: 10.5539/CCO.V4N1P14

L. Malik

引用次数: 0

Occult Breast Carcinoma Presenting With Anti-Ri-Associated Paraneoplastic Cerebellar Degeneration Revealed With FDG-PET FDG-PET显示隐匿性乳腺癌伴抗i相关副肿瘤小脑变性

Cancer and clinical oncology Pub Date : 2014-11-26 DOI: 10.5539/CCO.V4N1P9

A. Bazine, M. Fetohi, Maha Ait Berri, Y. Oufroukhi, M. Ichou, H. Errihani

引用次数: 0

Correlation of Dosimetric Parameters With Subclinical Liver Function Test Alterations After Radiotherapy for Upper Gastrointestinal Tract Tumors 剂量学参数与上消化道肿瘤放疗后亚临床肝功能改变的相关性

Cancer and clinical oncology Pub Date : 2014-10-31 DOI: 10.5539/CCO.V3N2P70

K. Malek, H. Zhang, Y. Boudam, M. Colonna, R. Sihanath, C. Rebischung, J. Balosso

{"title":"Correlation of Dosimetric Parameters With Subclinical Liver Function Test Alterations After Radiotherapy for Upper Gastrointestinal Tract Tumors","authors":"K. Malek, H. Zhang, Y. Boudam, M. Colonna, R. Sihanath, C. Rebischung, J. Balosso","doi":"10.5539/CCO.V3N2P70","DOIUrl":"https://doi.org/10.5539/CCO.V3N2P70","url":null,"abstract":"Purpose: To characterize conditions of radiation induced liver diseases (RILD) after radiation therapy administered for upper gastrointestinal tract tumours, not involving the liver. Method & Materials: this is a retrospective study of 169 patients treated by three dimensional conformal radiations for upper gastrointestinal tract tumours between 2002 and 2008 at the Michallon hospital. Cumulative and differential DVHs (Dose Volume Histogram) were extracted from TPS generated files and liver function tests (ALAT, ASAT, GGT and AP) and tumour markers (CA 19.9 and CEA) from patient records at four different time points (before treatment, and one, three, and six months after the end of treatment). Liver function alteration was defined as an increase in one parameter over 1.5 times the upper normal limit. All these data have been stored and statistically worked out using Lyman model parameters. Results: 34 patient records were studied. Twelve patients had RILD but none at six months. Results are consistent with the Burman description. Dosimetric profiles are different and a correlation appears between RILD and the level of doses given to liver. V40Gy is the most predictive dosimetric parameter for subclinical liver function changes. Conclusion: While dosimetric parameters are predictive of liver biological disorder, the Lyman model is not predictive of these mild disorders.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"3 1","pages":"70"},"PeriodicalIF":0.0,"publicationDate":"2014-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V3N2P70","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70722047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1